| 產(chǎn)品描述： | ME-401 (PWT-143, P110δ-IN-1)是一種口服的、有效的 Phosphatidylinositol 3-Kinase (PI3K) P110δ 的選擇性抑制劑，在細(xì)胞分析中的IC50值為0.6 nM |
| 靶點(diǎn)： |
P110δ(Cell-free assay):0.6 nM;PI3K |
| 體內(nèi)研究： |
ME-401 is an oral, once-daily, selective PI3Kδ inhibitor with an optimized pharmacologic profile that is in clinical development for the treatment of B-cell malignancies. ME-401 can be orally absorbed, distribute to target tissues, enter and accumulate in target cells, and bind to the target with high affinity to exert its mechanism of action. |
| 動(dòng)物實(shí)驗(yàn)： |
Animal Models: CD-1 mice, Sprague Dawley (SD) rats, Female BALB/c mice, Beagle dogs, Cynomolgus monkeys Dosages: 10 mg/kg for mice, 5 mg/kg for rats, 2 mg/kg for dogs and monkeys Administration: Oral gavage |
| 參考文獻(xiàn)： |
1. Ofir Moreno, et al. Clin Ther. 2018 Nov;40(11):1855-1867. 2. Ofir Moreno, Jamie Wood. Target Oncol. 2019 Oct;14(5):603-611. |
| 溶解性： |
Soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.654 ml |
8.268 ml |
16.535 ml |
| 5 mM |
0.331 ml |
1.654 ml |
3.307 ml |
| 10 mM |
0.165 ml |
0.827 ml |
1.654 ml |
| 50 mM |
0.033 ml |
0.165 ml |
0.331 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營許可證（不帶存儲(chǔ)）
營業(yè)執(zhí)照(三證合一)
北京